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Objective: To determine the effect of renal denervation (RDN) on the severity of
atherosclerosis and aortic aneurysm in hypertensive mice.
Methods: Hypertension, atherosclerosis and aortic aneurysm were induced by
subcutaneous infusion of angiotensin II (1 µg/kg/min) for 28 days in apolipoprotein
E-deficient mice. RDN was conducted using combined surgical and local chemical
denervation. The norepinephrine concentration in the kidney was measured by
high-performance liquid chromatography. Blood pressure was measured by the tail-cuff
method. Atherosclerosis was assessed by Sudan IV staining of the aortic arch. The aortic
diameter was measured by the morphometric method. The mRNA expression of genes
associated with atherosclerosis and aortic aneurysm were analyzed by quantitative PCR.
Results: RDN decreased the median norepinephrine content in the kidney by 93.4%
(n = 5–7, P = 0.003) 5 days after the procedure, indicating that the RDN procedure was
successful. RDN decreased systolic blood pressure in apolipoprotein E-deficient mice.
Mice that had RDN had more severe aortic arch atherosclerosis (median percentage
of Sudan IV positive area: 13.2% in control mice, n = 12, and 25.4% in mice having
RDN, n = 12, P = 0.028). The severity of the atherosclerosis was negatively correlated
with the renal norepinephrine content (spearman r = −0.6557, P = 0.005). RDN did
not affect the size of aortic aneurysms formed or the incidence of aortic rupture in mice
receiving angiotensin II. RDN significantly increased the aortic mRNA expression of matrix
metalloproteinase-2 (MMP-2).
Conclusion: RDN promoted atherosclerosis in apolipoprotein E-deficient mice infused
with angiotensin II associated with upregulation of MMP-2. The higher MMP-2 expression
could be the results of the greater amount of atheroma in the RDN mice. The findings
suggest further research is needed to assess potentially deleterious effects of RDN in
patients.
Keywords: angiotensin II, aortic aneurysm, atherosclerosis, blood pressure, matrix metalloproteinase-2, renal
denervation
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INTRODUCTION
Renal denervation (RDN) is used in clinical practice to lower
blood pressure in treatment-resistant hypertension (Krum et al.,
2009; Esler et al., 2010; Worthley et al., 2013; Bhatt et al., 2014;
Papademetriou et al., 2014) by inhibiting the sympathetic outflow
from the brain (Schlaich et al., 2009). RDN is generally regarded
as a safe procedure (Krum et al., 2009; Esler et al., 2010; Bhatt
et al., 2014). However, some studies have suggested that RDN
may cause renal artery stenosis in 5–18% of patients (Kaltenbach
et al., 2013; Worthley et al., 2013; Papademetriou et al., 2014;
Versaci et al., 2014).
A number of experimental studies suggest that both chemical
and surgical sympathetic denervation promote atherosclerosis
(Murphy et al., 1957; Snyder and Campbell, 1958; Kacem
et al., 1997, 2006; Kacem and Sercombe, 2008; Hachani
et al., 2010). A recent study reported that RDN inhibited
atherosclerosis formation in normotensive apolipoprotein E-
deficient (ApoE−/−) mice fed a high-fat diet (Wang et al., 2015).
The effects of RDN on atherosclerosis in mouse models that
have hypertension has not however been investigated. This is
important since RDN is performed in hypertensive patients.
This study was designed to investigate whether RDN affects
atherosclerosis severity in hypertensive ApoE−/− mice infused
with angiotensin II. As angiotensin II infusion also induces aortic
aneurysm we also assessed the effect of RDN on aortic aneurysm
severity.
METHODS
Animals
Male ApoE−/− mice (3 months old) were purchased from the
Animal Resources Centre, Perth, Australia. All experiments were
conducted in a temperature-controlled animal house (21 ± 1◦C)
under a 12:12-h light-dark cycle and mice were given standard
chow and water ad libitum. All animal protocols conformed to
the Guide for the Care and use of Laboratory Animals by the
United States National Institutes of Health and the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purpose (8th Edition, 2013). Institutional ethics approval was
obtained from both James Cook University and Federation
University Australia.
Experimental Protocol
A preliminary study was carried out to confirm the success of the
RDN procedure. Five ApoE−/− mice underwent sham surgery
and seven mice underwent bilateral RDN. Five days later, the
mice were euthanized and the right kidney was collected and
norepinephrine content determined.
For the main experiment, 18 ApoE−/− mice underwent
bilateral RDN and 20 ApoE−/− mice underwent sham surgery 1
day after the baseline blood pressure was measured (Figure 1).
Five days after RDN or sham surgery, blood pressure was
measured and all the mice were then subjected to angiotensin
II infusion at a dose of 1 µg/kg/min for the ensuing 28 days.
Blood pressure was measured at Day 14 and Day 27 after the
angiotensin II infusion commenced. The mice were euthanized
FIGURE 1 | A flowchart of the experiment. The baseline blood pressure
was measured followed by RDN or sham surgery on the next day. Five days
after RDN or sham surgery, blood pressure was measured and all the mice
were then subjected to angiotensin II infusion. Blood pressure was then
measured at Day 14 and Day 27 during the angiotensin II infusion. The mice
were euthanized at Day 28. Eight mice from the sham surgery group and six
mice from the RDN group died of aortic rupture during the 28-day angiotensin
II infusion. AngII, angiotensin II; BP, blood pressure; RDN, renal denervation.
at Day 28 (Figure 1) and the right kidney was collected for
norepinephrine content measurement, and the aorta was isolated
for morphometric analysis. The aortic arch was then used
for Sudan IV staining and the thoracic aorta used for RNA
extraction.
Renal Denervation
Bilateral RDN was carried out as previously described (O’Neill
et al., 1991; Ye et al., 1997). In brief, after the renal arteries and
veins were exposed, all visible nerves around the renal arteries
were cut, and connective tissues passing next to and along the
course of the renal arteries and veins were dissected and stripped
off the adventitia under a dissecting microscope with a 4×
magnification. Then the renal arteries and veins were painted
with a solution of 10% phenol in 95% ethanol (O’Neill et al., 1991;
Ye et al., 1997). After being washed with saline (0.9% sodium
chloride), the abdominal cavity was closed. For the mice in the
sham surgery group, the renal arteries were exposed as with the
RDN procedure, but the renal nerves were kept intact.
Norepinephrine Measurement
The right kidney was homogenized in 1 mM
ethylenediaminetetraacetic acid (EDTA) and 4 mM sodium
metabisulfite. The norepinephrine content in the homogenate
was measured by phase isocratic high-performance liquid
chromatography (HPLC) (Wang et al., 1999) coupled with an
electrochemical detector, with an Atlantis C18 column (5 µm
particle size, 4.6 × 150 mm) and a mobile phase of 50 mM
Na2HPO4, 27 µM EDTA, 0.6 mM sodium octane sulfonic
acid, and 3.5% acetonitrile (pH 4.0). This method had a good
reproducibility with an inter-assay coefficient of variation of
4.7% (n= 10).
Non-invasive Tail-cuff Blood Pressure
Measurement
Blood pressure was measured using a computerized, non-
invasive, tail-cuff system (Kent Scientific, USA) (Seto et al.,
2013). Animals were habituated to the device before measuring
blood pressure. Good reproducibility of this technique has been
established previously (Seto et al., 2013).
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Induction of Atherosclerosis and Aortic
Aneurysm
Atherosclerosis and aortic aneurysm were induced by
subcutaneous infusion of angiotensin II at a dose of 1 µg/kg/min
for 28 days (Daugherty et al., 2000). Briefly, under general
anesthesia using isoflurane, osmotic minipumps (Model 2004,
ALZET, USA) were placed into the subcutaneous space along the
dorsal midline to deliver 1 µg/kg/min of angiotensin (Sigma-
Aldrich, Castle Hill, Australia) dissolved in distilled water over
28 days.
Quantification of Atherosclerotic Lesion
Area
Atherosclerosis in the aortic arch was quantified by en face
staining as described previously (Krishna et al., 2012). Briefly,
the aortic arch was opened longitudinally and pinned down on
a wax coated petri-dish. Tissue samples were transferred to a 70%
ethanol solution and stained with 0.1% Sudan IV dissolved in
equal parts of acetone and 70% ethanol for 10 min to identify
areas of atherosclerosis. Sudan IV stained areas were quantified
using Adobe Photoshop software (version CS5.1) and expressed
as a percentage of the total aortic arch luminal surface area.
We have previously established that these measurements can be
repeated with good reproducibility (Golledge et al., 2010; Krishna
et al., 2012).
Measurement of the Diameter of the Aortic
Arch, Thoracic, and Suprarenal Aorta
After the 28-day infusion with angiotensin II, mice were
euthanized and aortas were harvested from their origin at the
left ventricle to the iliac bifurcation, placed beside a ruler, and
digitally photographed. The maximum diameters of the aortic
arch, thoracic aorta and the suprarenal aorta were determined
using the Adobe Photoshop CS5.1 software (Rush et al., 2009).
We have previously established that these measurements can be
repeated with good intraobserver reproducibility (Rush et al.,
2009).
Gene Expression Analysis
Six thoracic aortas were randomly selected from each group
for RNA extraction. RNA was extracted using the TRI-reagent
(Sigma-Aldrich, Castle Hill, Australia) in Eppendorf tubes
according to the manufacturer’s guidelines. The RNA yield of
one sample from the sham surgery group was too low and
not sufficient for the experiment, and thus this sample was not
used for the subsequent cDNA synthesis and quantitative PCR.
RNA was reverse transcribed to cDNA using the High Capacity
Reverse Transcription Kit (Life Technologies). Gene expression
was assessed by quantitative PCR using SYBR reagents. Primer
sets are outlined in Table 1. The cycling conditions were as
follows: a hold at 95◦C for 2 min, followed by 40 cycles at
95◦C for 15 s, 58◦C for 20 s, and 72◦C for 20 s. Relative gene
expression was assessed using the 2−11Ct method (Livak and
Schmittgen, 2001). Gene expression analysis was represented
using relative gene expression compared with the control gene
TABLE 1 | Primer sets.
Gene Primer Sets Tm (◦C) Product length
Adra2
F CAGCTCGCTGAACCCTGTTA 59.96 117
R CACGATGCGTTTTCTGTCCC 60.04
AT1A
F AGTTGGGAGGGACTGGATGA 59.88 149
R GTTAAGTCCGGGAGAGCAGC 60.46
AT1B
F GCAGGGAGTAACAGAGACCA 58.73 134
R GTGAATTCAAAATGCACCCGT 57.97
AT2
F TTTTAAGGAGTGCATGCGGGA 60.27 148
R GGTAATGTTTCTGCTGGTGGC 59.8
EEF2
F ACATGTCAGTCATCGCCCAT 59.46 166
R GAGATGGCGGTGGATTTGATTG 59.97
IL-6
F CGGCCTTCCCTACTTCACAA 59.68 149
R GCCATTGCACAACTCTTTTCTCA 60.24
iNOS
F CCTGCTTTGTGCGAAGTGTC 60.04 140
R CCCTTTGTGCTGGGAGTCAT 59.96
MCP-1
F CTTCTGGGCCTGCTGTTCA 59.93 127
R CCAGCCTACTCATTGGGATCA 59.23
MMP-2
F AACGGTCGGGAATACAGCAG 60.11 125
R GTAAACAAGGCTTCATGGGGG 59.18
MMP-9
F CAGCCGACTTTTGTGGTCTTC 59.74 87
R ATAGCGGTACAAGTATGCCTCTG 59.99
NF-κB
F GGCAGTGACGCGACGA 59.73 129
R AAACAGATCGTCCATGGTCAGG 60.36
TNF-α
F TAGCCCACGTCGTAGCAAAC 60.39 136
R ACAAGGTACAACCCATCGGC 60.32
Adra2, α2 adrenergic receptors; AT1A, type 1A angiotensin receptor; AT1B, type 1B
angiotensin receptor; AT2, type 2 angiotensin receptor; EEF2, eukaryotic translation
elongation factor 2; F, forward; IL-6, Interleukin-6; iNOS, inducible nitric oxide synthase;
MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; NF-κB,
Nuclear factor-kappa B; R, reverse; Tm, melting temperature; TNF-α, tumor necrosis
factor-alpha.
eukaryotic translation elongation factor 2 (EEF2) (Kouadjo et al.,
2007).
Plasma Cholesterol Measurements
Blood was collected by cardiac puncture at the time of
mice sacrifice. The concentration of total cholesterol, low-
density lipoprotein/very low-density lipoprotein (LDL/VLDL)
cholesterol and high-density lipoprotein (HDL) cholesterol in the
plasma were quantified using a commercial available kit (Abcam,
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San Francisco, CA, USA; catalog number: ab65390) (Wang et al.,
2014), according to the manufacturer’s instructions.
Statistical Analyses
Continuous numbers were presented as a median and
interquartile range (IQR). The difference between two groups
was analyzed using Mann-Whitney U-test. Blood pressure was
compared between mice that had RDN and controls during
the experimental period using a linear mixed effect (LME)
model using S Plus (software version 8.2). The difference in
survival between the two groups was analyzed using log rank
test. The correlation between atherosclerosis severity and renal
norepinephrine content was assessed using the correlation
analysis function of the GraphPad Prism 5 software (GraphPad
Software, Inc., La Jolla, CA, USA). Differences were considered
to be statistically significant at P < 0.05.
RESULTS
Baseline Parameters
The baseline body weight, systolic, diastolic and mean blood
pressure, and the heart rate were similar in the sham surgery and
the RDN groups (P > 0.05, Table 2).
Success of the RDN Procedure
In a preliminary study, we performed RDN in seven mice and
sham surgery in five mice. Five days later, mice were euthanized
and norepinephrine content in the kidney was determined. RDN
significantly decreased the median norepinephrine content in the
kidney by 93.4% (P = 0.003, Figure 2A), which is similar to the
previously reported ability of RDN to decrease norepinephrine
content by 95% (Nakashima et al., 1996), suggesting that the RDN
procedure was successful.
The norepinephrine in the kidney at the end of the main
experiment (i.e., at the end of the 28-day angiotensin II infusion)
was lower in the RDN group compared with sham surgery group
(P = 0.005, Figure 2B). The median norepinephrine content in
the RDN group was 71.7% of that in mice from the sham surgery
group, suggesting a sustained reduction in renal innervation
density.
The Effect of RDN on Blood Pressure
Baseline systolic, diastolic and mean blood pressure, and heart
rate were not significantly different in mice prior to RDN and
sham surgery (Figure 3). After RDN and sham surgery systolic
blood pressure was significantly lower in mice that had RDN
compared to controls (P = 0.017, Figure 3). Diastolic and mean
blood pressure were not significantly different in mice having
RDN and controls (Figure 3). RDN did not affect heart rate
(P > 0.05, Figure 3).
The Effect of RDN on Atherosclerosis
After 28 days of angiotensin II infusion, aortic arch Sudan
IV staining area was significantly greater in the RDN group
compared to the sham surgery group (P= 0.028, Figures 4A–C).
In addition, the norepinephrine content in the kidney at the end
of the experiment was negatively correlated with the Sudan IV
staining area (Figure 4D).
The Effect of RDN on Aortic Aneurysm
Severity
During the angiotensin II infusion, six mice died in the RDN
group and eight died in the sham surgery group due to aortic
rupture. There was no difference in the survival rate between
the two groups (P > 0.05, Figure 5A). Angiotensin II infusion
induced aortic aneurysm formation in the suprarenal and
thoracic aorta (Krishna et al., 2015). The maximum diameter
of the aortic arch, thoracic aorta and suprarenal aorta were not
significantly different in mice receiving RDN and sham surgery
(P > 0.05, Figures 5B–D).
FIGURE 2 | Norepinephrine content in the kidney of apolipoprotein
E-deficient mice. (A) Mice were euthanized 5 days after sham surgery or
RDN and the norepinephrine (NE) content in the kidney was determined. (B)
Mice were euthanized after 28 days angiotensin II infusion and then the NE
content in the kidney was determined. *P = 0.003, #P = 0.005, compared
with sham surgery.
TABLE 2 | The baseline parameters of the mice.
Group Body weight SBP DBP MAP Heart rate
(sample size) (g) (mm Hg) (mm Hg) (mm Hg) (beats/min)
Sham surgery(N = 20) 29.6 (28.6–31.0) 101.8 (96.5–103.5) 81.0 (77.5–85.1) 87.7 (83.5–90.8) 502 (437–613)
RDN (N = 18) 30.4 (29.2–31.1) 101.5 (96.5–106.0) 79.8 (74.4–84.3) 86.0 (83.0–90.7) 422 (364–564)
The baseline parameters were measured 1 day before the RDN or sham surgery procedures were conducted. Data were shown as a median and interquartile range (IQR). DBP, diastolic
blood pressure; g, gram; MAP, mean arterial blood pressure; N, number; RDN, renal denervation; SBP, systolic blood pressure.
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FIGURE 3 | Blood pressure and heart rate of the mice. Blood pressure and the heart rate were measured by the tail-cuff method at baseline (Day -6), 5 days after
RDN or sham surgery (Day 0), 14 days (Day 14) and 27 days (Day 27) after starting the angiotensin II infusion. SBP (#P = 0.017), but not DBP (P = 0.152) and MAP (P
= 0.076), was significantly lower in mice having RDN compared to controls, as analyzed by LME models. DBP, diastolic pressure; HR, heart rate; MAP, mean arterial
pressure; SBP, systolic blood pressure.
The Effect of RDN on the Aortic mRNA
Expression of Some Atherosclerosis
Associated Genes
mRNA expression of interleulin-6 (IL-6), inducible nitric oxide
synthase (iNOS), monocyte chemoattractant protein-1 (MCP-1),
nuclear factor-kappa B (NF-κB), tumor necrosis factor-alpha
(TNF-α) and matrix metalloproteinase-9 (MMP-9) within the
thoracic aorta were similar in mice receiving RDN and sham
surgery (Table 3). Mice receiving RDN had higher thoracic aortic
mRNA expression of MMP-2 than mice receiving sham surgery
(Figure 6).
The Effect of RDN on the Aortic mRNA
Expression of Angiotensin Receptors and
Adrenoceptors
mRNA expression of angiotensin receptors (both type 1 and 2)
and α2 adrenoceptors in the thoracic aorta were similar in mice
that received RDN and sham surgery (Table 3).
The Effect of RDN on Plasma Cholesterol
Levels
RDN did not affect plasma levels of LDL/VLDL cholesterol, HDL
cholesterol, or total cholesterol (P > 0.05, Figure 7).
DISCUSSION
This study focussed on assessing the effect of RDN on
atherosclerosis severity in a mouse model. RDN was successful
performed as evidenced by substantially lower norepinephrine
content of the kidney 5 and 33 days after the procedure and
lower systolic blood pressure in mice having RDN compared to
controls. The main finding of the study was that the severity of
aortic arch atherosclerosis, as assessed by Sudan IV staining area,
was greater inmice that received RDN than controls. The severity
of atherosclerosis was correlated with the extent of the RDN, as
assessed by renal norepinephrine levels. Our results suggest that
RDN did not affect aortic aneurysm severity or rupture.
A number of previous experimental studies have reported
that sympathetic denervation promoted atherosclerosis at sites
remote to the denervation procedure (Murphy et al., 1957;
Snyder and Campbell, 1958; Kacem et al., 1997, 2006; Kacem and
Sercombe, 2008; Hachani et al., 2010). Bilateral surgical lumbar
sympathectomy has been reported to increase atherosclerosis
severity in the thoracic and abdominal aorta, and iliac
and femoral arteries in rabbits fed a high cholesterol diet
(Murphy et al., 1957; Snyder and Campbell, 1958). Similarly,
sympathetic denervation induced by intravenous administration
of 6-hydroxydopamine was reported to increase atherosclerosis
within the basilar and femoral arteries of rabbits fed a high
cholesterol diet (Kacem et al., 2006; Kacem and Sercombe, 2008).
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FIGURE 4 | RDN promoted more severe atherosclerosis in the
apolipoprotein E-deficient mice infused with angiotensin II. Mice were
euthanized after infusion with angiotensin II for 28 days, and the aortas were
collected. The surface of the aortic arch was stained en face with Sudan IV.
(A,B) were representative Sudan IV images of the aortic arch from sham
surgery and RDN groups, respectively. The percentage of Sudan IV-positive
area was calculated and expressed as a percentage of the total aortic arch
luminal surface area (C). (D) The correlation between the norepinephrine (NE)
content in the kidney and atherosclerosis in the aortic arch.
Sympathetic denervation by subcutaneous administration of
guanethidine was reported to promote intima thickening within
the abdominal aorta of rats fed a high cholesterol diet (Hachani
et al., 2010).
The mechanisms underlying the atherosclerosis-promoting
effect of sympathetic denervation are not well understood. It has
been reported that this effect of sympathetic denervation may
be due to stimulating migration of adventitial fibroblasts to the
media and the associated loss and dedifferentiation of smooth
muscle cells (Kacem and Sercombe, 2008; Hachani et al., 2010).
It has been reported that following sympathetic denervation that
the aortic expression of immature smooth muscle cell markers,
such as vimentin, increased but that the expression of the
mature smooth muscle cell markers (α-smooth muscle actin,
h-caldesmon) decreased (Hachani et al., 2010). However, the
importance of these changes in smooth muscle cell phenotype on
the development of atherosclerosis have not been established.
Our results are in contrast to the results of a recent
report which used another atherosclerotic model, i.e., ApoE−/−
mice fed a high-fat diet for 10 weeks (Wang et al., 2015).
That study Wang et al. (2015) reported that RDN decreased
atherosclerosis as assessed by oil-red-O staining within the aortic
root and the aortic tree (including aortic arch, brachiocephalic
artery, common carotid arteries and subclavian arteries). The
discrepancy may be due to the disparate animal models used,
i.e., high-fat diet vs. angiotensin II infusion in our study.
FIGURE 5 | RDN did not affect aortic rupture and the severity of the
aortic aneurysm in the apolipoprotein E-deficient mice infused with
angiotensin II. (A) Mice in the sham surgery and RDN groups were
subcutaneously infused with angiotensin II for 28 days. The death of mice was
recorded during this period and the survival curves were then constructed. P
= 0.299 between the two survival curves using log rank test. (B–D) Mice were
euthanized after infusion with angiotensin II for 28 days. The aorta was then
dissected for aortic aneurysm assessment. The maximal aortic diameter in the
aortic arch (B), thoracic (C), and suprarenal (SRA, D) aorta were measured.
TABLE 3 | The effect of RDN on mRNA expression of pro-atherosclerosis
markers, angiotensin receptors, and α2 adrenergic receptors.
Sham RDN
AT1A 0.801 (0.735–1.364) 0.984 (0.574–1.295)
AT1B 0.834 (0.004–1.996) 0.039 (0.005–0.534)
AT2 0.803 (0.657–1.442) 1.669 (0.559–2.252)
Adra2 1.076 (0.784–1.178) 0.951 (0.546–1.293)
IL-6 1.011 (0.713–1.282) 0.501 (0.312–1.402)
iNOS 1.022 (0.741–1.0248) 1.311 (0.429–1.872)
MCP-1 0.633 (0.431–1.713) 0.433 (0.300–0.587)
NF-κB 0.951 (0.724–1.300) 0.890 (0.628–1.369)
MMP-9 0.969 (0.778–1.238) 1.472 (0.761–2.281)
TNF-α 0.863 (0.709–1.359) 0.992 (0.613–1.273)
Mice were euthanized after infusion with angiotensin II for 28 days, and the thoracic
aortic was used for RNA extraction. mRNA expression was analyzed using quantitative
PCR. The relative gene expression was normalized using EEF2 as a reference gene. Data
were expressed as median and interquartile range. N = 5 for sham surgery, and N =
6 for RDN. P > 0.05 for all the genes tested in the table. Adra2, alpha-2 adrenergic
receptor; AT1A, type 1A angiotensin receptor; AT1B, type 1B angiotensin receptor; AT2,
type 2 angiotensin receptor; IL, interleukin; iNOS, inducible nitric oxide synthase; MCP-
1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; NF-κB, nuclear
factor-kappa B; RDN, renal denervation; TNF-α, tumor necrosis factor-alpha.
The angiotensin II infusion model represents an advanced
atherosclerosis model, as suggested by the large Sudan IV
staining area reported in our study (Wang et al., 2015). In
addition, the angiotensin II infusion model is a hypertensive
model, whereas the high-fat diet model is a normotensive model.
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FIGURE 6 | The effect of RDN on the mRNA expression of MMP-2. Mice
were euthanized after infusion with angiotensin II for 28 days, and the thoracic
aortic was used for RNA extraction. mRNA expression was analyzed using
quantitative PCR. The relative gene expression was normalized using EEF2 as
a reference gene. N = 5 for sham surgery, and N = 6 for RDN. MMP, matrix
metalloproteinase.
The latter model is different from the clinical setting as RDN is
performed in treatment-resistant hypertensive patients.
MMP-2 expression within the thoracic aorta was greater
in mice receiving RDN than controls. MMP-2 plays an
important role in degrading extracellular matrix and has
been implicated in the initiation, development and eventual
rupture of atherosclerotic plaques (Li et al., 1996; Nagase and
Woessner, 1999; Johnson et al., 2006; Kuzuya et al., 2006).
It has been reported that MMP-2 protein and activity levels
are increased in human aortic atherosclerotic lesions compared
with normal regions of the aorta (Li et al., 1996). The severity
of atherosclerosis in MMP-2 and ApoE double gene knockout
mice has been reported to be less than that in ApoE single
gene knockout mice (Kuzuya et al., 2006). The activity of
MMP-2 and other MMPs can be inhibited by their endogenous
tissue inhibitors (TIMPs) (Nagase and Woessner, 1999). It has
been reported that over-expression of TIMP-2 by adenovirus
technology significantly reduces atherosclerotic formation in
the brachiocephalic artery of ApoE−/− mice fed a high-fat
diet (Johnson et al., 2006), and over-expression of TIMP-
2 has also been reported to promote atherosclerotic plaque
stability (Johnson et al., 2006). It is therefore possible that the
upregulation of MMP-2 identified in mice receiving RDN may
have promoted atherosclerosis within the aorta. It is also possible
that the higher MMP-2 expression measured simply reflected
the greater atherosclerosis in the mice receiving RDN although
the fact other atherosclerosis-associated genes were not different
supports a causative association. Further studies are needed to
examine this theory. The expression of a range of other genes
implicated in inflammation and matrix remodeling and plasma
lipids were similar in mice receiving RDN and controls.
Other possible explanation for the greater atherosclerosis
in mice receiving RDN include increased arterial pressure
FIGURE 7 | Plasma lipid concentrations in mice undergoing RDN and
controls. Plasma lipid concentrations were measured in blood collected at the
completion of the 28-day angiotensin II infusion. N = 10 for each group. HDL,
high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density
lipoprotein.
variability or functional changes within the media. These have
not been investigated in the current study.
RDN has been reported to promote renal artery stenosis
in humans. The Symplicity HTN studies (Krum et al., 2009;
Esler et al., 2010; Bhatt et al., 2014) reported a renal artery
stenosis rate of 0.3–2.2%, whereas other trials with smaller
sample sizes have reported a higher rate of 2.8–18% (Kaltenbach
et al., 2013; Worthley et al., 2013; Papademetriou et al., 2014;
Persu et al., 2014; Versaci et al., 2014). The EnligHTN I trial
(Worthley et al., 2013) reported that the progression of pre-
existing renal artery stenosis was possibly related to the RDN
procedure. Atherosclerosis is responsible for most primary renal
artery stenoses but those developing after RDN may represent
a local intimal hyperplasia response to the procedure rather
than promotion of pre-existing atherosclerosis as identified in
the mouse model studies here (Lao et al., 2011). Whether the
renal artery stenoses reported in these trials are related to the
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promotion of atherosclerosis within the distant site of the aortic
arch found in the current mouse study is not clear.
Renal denervation has been shown to decrease blood pressure
in a large number of clinical (Krum et al., 2009; Esler et al., 2010)
and preclinical (Nishihara et al., 2016) studies. However, the
recent blinded, sham-controlled, randomized Symplicity HTN-3
trial (Bhatt et al., 2014) and a number of non-randomized trials
(Brinkmann et al., 2012; Vase et al., 2012; Fadl Elmula et al., 2013;
Hart et al., 2013; Ezzahti et al., 2014) suggested that RDN did not
decrease blood pressure, and this may be due to an ineffective
RDN procedure (Mahfoud et al., 2015). Currently there are no
well-defined ways to immediately tell whether RDN has been
technically successful in patients (Mahfoud et al., 2015). RDN
was successful in our experiment as indicated by a substantial
decrease in the renal norepinephrine content, and this was
associated with a decrease in systolic blood pressure. RDN in
our study did not affect heart rate, which is consistent with other
reports (Bhatt et al., 2014; Vink et al., 2014).
Limitations
This study has several limitations. First, the sample size of the
study was small; second, this study employed only one animal
model; third, blood pressure was measured by the tail-cuff
method rather than the gold standard telemetry method; and
fourth, the RDN procedure in mice is different from the clinical
practice in which catheter-based methods are used. Finally the
plasma concentrations of lipids varied substantially in different
mice and the reasons for this are not clear.
Potential Clinical Implication
Based on our results and other experimental evidence (Murphy
et al., 1957; Snyder and Campbell, 1958; Kacem et al., 1997,
2006; Kacem and Sercombe, 2008; Hachani et al., 2010), there
is concern that RDN might promote more severe distant
atherosclerosis severity. Clinical studies are needed to examine
this possibility in patients undergoing RDN.
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